Metheor Therapeutics Corp is a biotechnology company designing and developing inhibitors of DNA methyltransferase enzymes (DNMTs).  Our goal is to produce novel therapeutic compounds that will have a role in the treatment of cancers and other major diseases.  While there are two approved DNMT inhibitors being used to treat Myelodysplastic Syndromes (Vidaza and Dacogen), there is a need for new treatments with selective pharmocology and improved toxicity profiles.  Our novel approach addresses this need.